An Open-Label Extension Study to Assess Long-term Safety and Tolerability of Batoclimab in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518364-12-00

Acronym

IMVT-1401-2402

Enrollment

Registered

2025-04-01

Start date

2025-05-09

Completion date

Unknown

Last updated

2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Brief summary

Proportion of participants with TEAEs, SAEs, and TEAEs leading to study treatment discontinuation.

Detailed description

Change from baseline over time in the following scores: • Adjusted INCAT • Mean Grip Strength

Interventions

DRUGBatoclimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of participants with TEAEs, SAEs, and TEAEs leading to study treatment discontinuation.	—

Secondary

Measure	Time frame
Change from baseline over time in the following scores: • Adjusted INCAT • Mean Grip Strength	—

Countries

Belgium, Bulgaria, Denmark, Germany, Greece, Italy, Norway, Poland, Romania, Slovakia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026